NCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
Clinical Trials
3 trialsNCT04951947 2024-09-19
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Recruiting
NCT05296603 2024-01-10
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Unknown